Literature DB >> 20598352

Prognostic significance of Aurora-A expression in human bladder cancer.

Yu Lei1, Sun Yan, Lei Ming-De, Li Na, Han Rui-Fa.   

Abstract

Aurora-A is an oncogenic serine/threonine kinase, which plays important roles in tumorigenesis, development and chemoresistance of human cancers. The aim of the study was to detect the expression of Aurora-A gene in bladder cancer tissues and analyze its association with prognosis of bladder cancer patients. RT-PCR was performed to detect the expression of Aurora-A mRNA in 20 cases of bladder cancer and corresponding non-tumor tissue samples. Immunohistochemistry was performed to detect the localization of Aurora-A protein in 96 cases of bladder cancer tissue samples. Associations between Aurora-A protein expression and clinico-pathological factors or survival of bladder cancer patients were statistically analyzed. It was found that the expression levels of Aurora-A mRNA in bladder cancer tissues (1.08±0.24) were significantly higher than those in corresponding non-tumor tissues (0.22±0.07; P<0.01). Moreover, immunohistochemical staining results showed the localization of Aurora-A protein to be mainly located in the cytoplasm of bladder cancer cells. High levels of Aurora-A protein expression were correlated with pathological stage (P=0.007), lymph node metastasis (P=0.014) and venous invasion (P=0.008), but not with other factors including age, gender, tumor grade and recurrence of superficial cancer. Patients with high expression levels of Aurora-A protein showed lower disease-free and overall survival rates than those with low expression levels (P=0.0072 and 0.0009, respectively). Univariate and multivariate analysis of prognostic factors in bladder cancer patients indicated that Aurora-A expression was an independent unfavorable prognostic factor (hazard ratio: 0.673; 95% confidence interval: 0.388-0.912; P<0.001). Our study suggests that overexpression of Aurora-A gene may play an important role in the progression of bladder cancer and that Aurora-A expression is an independent factor for predicting the prognosis of bladder cancer in patients.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598352     DOI: 10.1016/j.acthis.2010.05.004

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  13 in total

1.  Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib.

Authors:  Andrea Necchi; Giulia Pintarelli; Daniele Raggi; Patrizia Giannatempo; Francesca Colombo
Journal:  Invest New Drugs       Date:  2017-02-03       Impact factor: 3.850

2.  Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer.

Authors:  Michela de Martino; Shahrokh F Shariat; Sebastian L Hofbauer; Ilaria Lucca; Christopher Taus; Helene G Wiener; Andrea Haitel; Martin Susani; Tobias Klatte
Journal:  World J Urol       Date:  2014-02-23       Impact factor: 4.226

3.  The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer.

Authors:  Jayoung Kim; Wun-Jae Kim; Zhiqian Liu; Massimo Loda; Michael R Freeman
Journal:  Cell Cycle       Date:  2012-03-15       Impact factor: 4.534

4.  Expression of hedgehog pathway components is associated with bladder cancer progression and clinical outcome.

Authors:  Hui-Chan He; Jia-Hong Chen; Xi-Bin Chen; Guo-Qiang Qin; Chao Cai; Yu-Xiang Liang; Zhao-Dong Han; Qi-Shan Dai; Yan-Ru Chen; Guo-Hua Zeng; Jian-Guo Zhu; Fu-Neng Jiang; Wei-de Zhong
Journal:  Pathol Oncol Res       Date:  2011-08-24       Impact factor: 3.201

5.  Aurora-A modulates MMP-2 expression via AKT/NF-κB pathway in esophageal squamous cell carcinoma cells.

Authors:  Xiaoxia Wang; Xiaozhong Li; Chaohui Li; Chun He; Benhong Ren; Qing Deng; Wei Gao; Binquan Wang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-04-28       Impact factor: 3.848

6.  The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Authors:  Ning Zhou; Kamini Singh; Maria C Mir; Yvonne Parker; Daniel Lindner; Robert Dreicer; Jeffrey A Ecsedy; Zhongfa Zhang; Bin T Teh; Alexandru Almasan; Donna E Hansel
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

7.  Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer.

Authors:  Shiying Zhang; Jianye Li; Gaobiao Zhou; Dawei Mu; Jingmin Yan; Jizhang Xing; Zhiyong Yao; Haibo Sheng; Di Li; Chao Lv; Bin Sun; Quan Hong; Heqing Guo
Journal:  Tumour Biol       Date:  2015-11-07

8.  Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.

Authors:  Enke Baldini; Chiara Tuccilli; Natalie Prinzi; Salvatore Sorrenti; Laura Falvo; Corrado De Vito; Antonio Catania; Francesco Tartaglia; Renzo Mocini; Carmela Coccaro; Stefania Alessandrini; Susi Barollo; Caterina Mian; Alessandro Antonelli; Enrico De Antoni; Massimino D'Armiento; Salvatore Ulisse
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

9.  SATB1 overexpression regulates the development and progression in bladder cancer through EMT.

Authors:  Feng Wan; Chao Cheng; Zongwei Wang; Xingyuan Xiao; Hanqing Zeng; Shian Xing; Xuepan Chen; Jin Wang; Sen Li; Youpeng Zhang; Wei Xiang; Zhineng Zhu; Cameron Johnson; Zhaohui Zhu
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

10.  Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC).

Authors:  Benedicte Martin; Franck Chesnel; Jean-Guy Delcros; Florence Jouan; Anne Couturier; Frederic Dugay; Xavier Le Goff; Jean-Jacques Patard; Patricia Fergelot; Cecile Vigneau; Nathalie Rioux-Leclerq; Yannick Arlot-Bonnemains
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.